Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Fraunhofer scientists use antibodies to detect cancer cells in tissue samples

Antibodies combat viruses and bacteria. They also attach themselves to cancer cells - in a typical, characteristic way. Fraunhofer scientists are using this property to detect cancer cells in tissue samples. Such rapid tests can already be applied by surgeons during operations - within a few minutes and without expensive equipment.

4 Jan 2016

Myostatin antibody shows promise in treating age-related decline in muscle mass and power

A proof-of-concept, phase 2 trial by an international research team has found promising results for a myostatin antibody in treating the decline in muscle mass and power associated with aging.

29 Dec 2015

Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Diabetes is the leading cause of kidney failure, and scientists have found that infusing just a small dose of a cytokine, thought to help cause that failure, can instead prevent or reverse it.

29 Dec 2015

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune Pharmaceuticals Inc. a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific antibodies.

29 Dec 2015

Study shows why immune system fails to develop immunity during malaria infection

Australian scientists have for the first time revealed how malaria parasites cause an inflammatory reaction that sabotages our body's ability to protect itself against the disease.

26 Dec 2015

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

24 Dec 2015

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Lower levels of antibodies in saliva linked to increased risk of mortality

New research from the University of Birmingham has found that lower levels of antibodies in saliva are associated with of an elevated risk of mortality, and could be an early indicator of risk.

24 Dec 2015

Single VRC01 antibody infusion could suppress HIV level in people not taking ART

A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in a paper published today.

24 Dec 2015

Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Janardan Pandey, Ph.D., an immunogeneticist specializing in immunoglobulin GM genes at the Medical University of South Carolina, helped monitor for immune responses that could limit the effectiveness of the broadly neutralizing antibody VRC01 in a phase 1 trial of that antibody in HIV-infected individuals led by a team at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

24 Dec 2015

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

More patients with advanced non-small-cell lung cancer (NSCLC) could benefit from pembrolizumab, says Professor Roy Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, presenting promising results from the pivotal phase 2/3 KEYNOTE-010 trial at the first ESMO Asia Congress in Singapore), in conjunction with a publication in The Lancet.

22 Dec 2015

Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 and ROR2, to accelerate the proliferation and spread of chronic lymphocytic leukemia (CLL) cells, the most common form of blood cancer in adults.

22 Dec 2015

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

A new study has found immunotherapy to be more effective than chemotherapy in treating most previously treated patients with advanced lung cancer, and demonstrated effectiveness in a wider population of people than previously known to benefit from the therapy.

22 Dec 2015

Targeted alpha therapy has potential to reduce HIV-infected cells from central nervous system

Targeted alpha therapy has the potential to selectively eliminate HIV infected cells from the central nervous system, according to a recent study co-authored by the JRC. The study shows that a specific human antibody labelled with the alpha emitter bismuth-213 can penetrate the blood brain barrier and selectively target and destroy HIV-infected cells while sparing non-infected healthy cells.

21 Dec 2015

GeNeuro initiates GNbAC1 Phase IIb study in Relapsing-Remitting Multiple Sclerosis

GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has initiated its planned Phase IIb study “CHANGE-MS” (Clinical trial assessing the HERV-W Env ANtagonist GNbAC1 for Efficacy in Multiple Sclerosis) with its lead antibody GNbAC1 in Relapsing-Remitting Multiple Sclerosis (RRMS).

21 Dec 2015

MorphoSys implements Dotmatics’ Vortex to improve antibody research

Dotmatics, a leading provider of scientific informatics solutions and services, announced MorphoSys will implement Vortex to analyse and visualise their screening data enabling rapid, informed decision making. MorphoSys choose Vortex because of the intuitive nature of the product and its extensive drug discovery capabilities.

21 Dec 2015

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore.

17 Dec 2015

UMMS researchers identify new life cycle stage in HIV infection

Researchers at the University of Massachusetts Medical School have identified a new life cycle stage in HIV infection, thanks to a novel technique they developed to take images of intact infected cells.

17 Dec 2015

TSRI scientists track how HIV-fighting antibodies develop over time

In a new study, a team led by scientists at The Scripps Research Institute tracked how a family of these HIV-fighting antibodies develops over time. The research shows how a future vaccine might trigger the immune system to produce these antibodies more effectively.

16 Dec 2015

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Researchers have found that a prophylaxis treatment can prevent new-onset hepatitis B in children who receive liver transplants from donors who were previously infected with hepatitis B virus (HBV) but had successfully cleared the virus.

16 Dec 2015

Antibody News and Research

Further Reading

Fraunhofer scientists use antibodies to detect cancer cells in tissue samples

Myostatin antibody shows promise in treating age-related decline in muscle mass and power

Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Study shows why immune system fails to develop immunity during malaria infection

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Lower levels of antibodies in saliva linked to increased risk of mortality

Single VRC01 antibody infusion could suppress HIV level in people not taking ART

Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

Targeted alpha therapy has potential to reduce HIV-infected cells from central nervous system

GeNeuro initiates GNbAC1 Phase IIb study in Relapsing-Remitting Multiple Sclerosis

MorphoSys implements Dotmatics’ Vortex to improve antibody research

Novel strategies on the way for difficult-to-treat head and neck cancer

UMMS researchers identify new life cycle stage in HIV infection

TSRI scientists track how HIV-fighting antibodies develop over time

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Antibodies eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News